New Registrations
Kenya's Pharmaceutical Landscape: 40 New Drug Registrations in May 2026
Kenya saw 40 new pharmaceutical registrations in May 2026. This AfriReg analysis reveals key trends in therapeutic areas and active companies shaping market access.
Kenya's pharmaceutical sector demonstrated robust growth in May 2026, with 40 new drug registrations added in the last 30 days. This surge reflects a dynamic market, expanding patient access to crucial medications, and highlighting strategic moves by both local and international players.
AfriReg's analysis of these new registrations provides valuable insights for regulatory teams, market access professionals, and business development strategists operating within or looking to enter the Kenyan market.
Key Therapeutic Areas Seeing Expansion
The latest registrations showcase a diverse range of therapeutic areas, indicating a focus on addressing both chronic diseases and acute conditions prevalent in the region. Notable areas include:
- Diabetes Management: Drugs like DAPAGOOD 5 (Dapagliflozin), EMPAGOOD 10 L (empagliflozin and linagliptin), TRUGLYX 0.25 (Semaglutide), and Galvusmet (vildagliptin+metformin) highlight a significant push in novel oral and injectable anti-diabetics. This signals a growing burden of metabolic diseases and a competitive landscape for innovative diabetes solutions.
- Pain Management & Anti-inflammatories: The registration of Ketesse (Dexketoprofen), NAPRIN (Naproxen), Gabica (Pregabalin), CABALIN 25 (Pregabalin), and LEVIPIL 250MG TABLETS (Levetiracetam) indicates expansion in both common pain relief and neuropathic pain management. Fentanyl and Morphine Sulphate injections also reinforce the availability of strong analgesics.
- Gastrointestinal Health: Products such as Movicol (Sodium Chloride, Polyethylene Glycol), Esofag- 40 (Esomeprazole), Eso-Q 40mg Tablet (Esomeprazole), and Duspatalin (Mebeverine Hydrochloride) point to continued demand for treatments for digestive disorders and reflux.
- Anti-infectives: While not the dominant category, registrations like VORIOLE 50 (Voriconazole), Flutrox 200 (Fluconazole), PENEM INJECTION (Meropenem), FLUCILLIN 250 (Flucloxacillin Sodium), and STREPTO 1 (streptomycin) underscore the ongoing need for broad-spectrum anti-fungal and antibacterial agents.
- Cardiovascular & Renal Conditions: UNIZAR FORTE (Lorsartan Potassium, Amlodipine), METOZ 5 TABLETS (Metolazone), and AMNOL 4 mg Injection (Zoledronic Acid Monohydrate) indicate efforts to address hypertension, edema, and bone health concerns often tied to cardiovascular and renal diseases.
- Oncology & Immunomodulators: MABTHERA 100 (RITUXIMAB), PREZISTA 600mg (Darunavir), EDURANT (Rilpivirine), and LINADEX 25 (Lenalidomide) demonstrate a critical expansion in advanced treatments for cancer and HIV, signaling the market's readiness for high-value specialty pharmaceuticals.
Most Active Pharmaceutical Companies
Analysis of the registrants reveals a mix of established global pharmaceutical giants and active regional players:
- Janssen-Cilag International NV: With multiple HIV medication registrations (PREZISTA, EDURANT), Janssen continues to strengthen its presence in critical public health areas.
- Hetero Labs Limited: A prominent Indian manufacturer, Hetero Labs shows significant activity with registrations like TRUGLYX 0.25, Sedafol, and LINADEX 25, indicating a broad therapeutic focus and competitive pricing strategy.
- ZAIN PHARMA LIMITED: A local Kenyan player, ZAIN PHARMA has successfully registered multiple diabetes medications (DAPAGOOD 5, EMPAGOOD 10 L), demonstrating capacity for local manufacturing or strategic partnerships to bring essential drugs to market.
- Getz Pharma (Pvt) Limited: Another active international player with registrations like Solifen 5 mg Tablets and Gabica 50 mg Capsules, expanding access to urological and neurological treatments.
- Universal Corporation Limited & DAWA LIMITED: These Kenyan-based companies continue to contribute to the domestic supply chain, with products like Flutrox 200 and Bilas Oral solution, respectively.
This demonstrates a healthy ecosystem where multinational pharmaceutical companies introduce innovative, often high-cost treatments, while regional and local players contribute to the availability of generics and essential medicines across a wider patient base.
Implications for Market Access
The influx of these 40 new registrations presents several key implications for market access in Kenya:
- Increased Competition: Specialized therapeutic areas, particularly diabetes and certain anti-infectives, are becoming more crowded. Companies will need robust market access strategies, including health economics and outcomes research (HEOR), to differentiate their products.
- Focus on Chronic Disease Management: The continued high number of registrations for diabetes, cardiovascular, and pain management drugs underscores the growing prevalence of non-communicable diseases (NCDs) in Kenya. This creates opportunities for companies that can offer comprehensive disease management solutions, not just individual drugs.
- Role of Local Manufacturing and Distribution: The activity of local entities like ZAIN PHARMA LIMITED, Universal Corporation Limited, and DAWA LIMITED indicates the importance of local partnerships or strong distribution networks for successful market penetration and supply chain resilience.
- Regulatory Efficiency: The sheer volume of registrations suggests a reasonably efficient regulatory pathway for quality products. Understanding the nuances of the Pharmacy and Poisons Board (PPB) process is crucial for timely market entry.
- Pricing and Affordability: With an expanding formulary, pricing pressure will likely intensify, especially for drugs with multiple generic or biosimilar entrants. Strategies around affordability, patient support programs, and public-private partnerships will become more critical.
Snapshot of New Registrations (May 2026)
| Drug | Holder | Country | Status | Date Added |
|---|---|---|---|---|
| Movicol (Sodium Chloride BP 350.7mg, Polyethylene Glycol…) | Win Medicare Private Limited | Kenya | active | 29 May 2026 |
| NAPRIN (Naproxen) | UNIJULES LIFE SCIENCES LTD B# 35 & 36, MIDC… | Kenya | active | 29 May 2026 |
| Ketesse (Dexketoprofen (as trometamol salt)) | Menarini International Operations Luxembourg S.A | Kenya | active | 29 May 2026 |
| DAPAGOOD 5 (Dapagliflozin Propanediol monohydrate) | ZAIN PHARMA LIMITED | Kenya | active | 29 May 2026 |
| EMPAGOOD 10 L (empagliflozin and linagliptin) | ZAIN PHARMA LIMITED | Kenya | active | 29 May 2026 |
| IDEOS (Calcium Carbonate 500mg/ Cholecalciferol…) | LABORATOIRE INNOTECH INTERNATIONAL | Kenya | active | 29 May 2026 |
| MABTHERA 100 (RITUXIMAB) | F. HOFFMAN-LA ROCHE LTD | Kenya | active | 27 May 2026 |
| PROBETA EYE / EAR / NOSE DROPS (BETAMETHASONE SODIUM PHOSPHATE) | ATCO Laboratories Limited | Kenya | active | 27 May 2026 |
| TRUGLYX 0.25 (Semaglutide) | HETERO LABS LIMITED | Kenya | active | 27 May 2026 |
| VORIOLE 50 (Voriconazole) | MSN Laboratories Private Limited | Kenya | active | 27 May 2026 |
| Glandin E 2 Tablet 3mg (Dinoprostone) | Nabiqasim Industries (Pvt). Ltd. | Kenya | active | 27 May 2026 |
| Fentanyl 50mcg/ml Solution for Injection (Fentanyl Citrate) | Martindale Pharmaceuticals | Kenya | active | 27 May 2026 |
| Sedafol (Propofol) | M/s. Hetero Labs Limited | Kenya | active | 27 May 2026 |
| Flutrox 200 (Fluconazole) | Universal Corporation Limited | Kenya | active | 27 May 2026 |
| Solifen 5 mg Tablets (Solifenacin Succinate) | Getz Pharma (Pvt) Limited | Kenya | active | 27 May 2026 |
| PENEM INJECTION (Meropenem for injection USP) | Syner-Med Pharmaceuticals (K) Ltd | Kenya | active | 27 May 2026 |
| Esofag- 40 (Esomeprazole) | Micro Labs Limited | Kenya | active | 27 May 2026 |
| Implanon NXT (Etonogestrel) | N. V. Organon B.V. | Kenya | active | 27 May 2026 |
| Bilas Oral solution (Bilastine) | DAWA LIMITED | Kenya | active | 27 May 2026 |
| PREZISTA 600mg (Darunavir) | Janssen-Cilag International NV | Kenya | active | 27 May 2026 |
| PREZISTA 75 mg (Darunavir) | Janssen-Cilag International NV | active | 27 May 2026 | Kenya |
| G-KIT (Amoxicillin Tablets BP 1000 mg, Clarithromycin…) | PRO MED PHARMACEUTICALS LTD | Kenya | active | 27 May 2026 |
| Eso-Q 40mg Tablet (Esomeprazole) | Q PHARMA DMCC | Kenya | active | 27 May 2026 |
| Morphine Sulphate Injection BP 10mg in 1ml (Morphine Sulphate) | Macarthys Laboratories Ltd T/a Martindale… | Kenya | active | 27 May 2026 |
| Galvusmet tablets 50/500mg (vildagliptin+metformin) | Novartis Pharma Services Inc | Kenya | active | 27 May 2026 |
| LINADEX 25 (Lenalidomide) | Hetero Labs Limited | Kenya | active | 27 May 2026 |
| CABALIN 25 (Pregabalin) | GALAXY PHARMACEUTICAL LIMITED | Kenya | active | 27 May 2026 |
| Gabica 50 mg Capsules (Pregabalin) | Getz Pharma (Pvt) Limited | Kenya | active | 27 May 2026 |
| EDURANT (Rilpivirine) | Janssen-Cilag International NV | Kenya | active | 27 May 2026 |
| METOZ 5 TABLETS (Metolazone) | Centaur Pharmaceuticals Pvt. Ltd. | Kenya | active | 27 May 2026 |
| AMNOL 4 mg Injection (Zoledronic Acid Monohydrate) | Venus Remedies Limited | Kenya | active | 27 May 2026 |
| FLUCILLIN 250 (Flucloxacillin Sodium BP) | Theon Pharmaceuticals Ltd | Kenya | active | 27 May 2026 |
| STREPTO 1 (streptomycin (as sulphate) BP) | CROWN HEALTHCARE | Kenya | active | 27 May 2026 |
| Pred Forte Sterile Eye Suspension (Prednisolone acetate) | Allergan Pharmaceuticals (pty) ltd | Kenya | active | 27 May 2026 |
| UNIZAR FORTE (Lorsartan Potassium, Amlodipine &…) | MEDISEL KENYA LIMITED | Kenya | active | 27 May 2026 |
| Tobrex Eye Drops (Tobramycin) | Novartis Pharma AG | Kenya | active | 27 May 2026 |
| Duspatalin 135 mg Tablets (Mebeverine Hydrochloride) | Abbott Laboratories S.A. (Pty) Ltd | Kenya | active | 27 May 2026 |
| Talgentis (tadalafil) | ISIS PHARMACEUTICALS | Kenya | active | 27 May 2026 |
| Humulin N (Human Insulin) | Eli Lilly Exports S.A | Kenya | active | 27 May 2026 |
| LEVIPIL 250MG TABLETS (Levetiracetam) | Sun Pharmaceutical Industries Limited | Kenya | active | 27 May 2026 |
AfriReg Pro empowers regulatory teams by automating the tracking of such dynamic market shifts. With real-time updates and granular data on drug registrations, regulatory changes, and competitive landscapes across African markets, AfriReg Pro helps teams anticipate trends, optimize market entry strategies, and ensure compliance without manual data sifting.